{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:38:30Z","timestamp":1790289510896,"version":"4.1.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,30]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Mirikizumab, an IL-23p19 monoclonal antibody, has emerged as a promising therapy for inflammatory bowel disease (IBD). However, the efficacy of different induction doses has not been comprehensively summarized. This systematic review and meta-analysis evaluated the effectiveness of mirikizumab induction therapy across multiple dose regimens at 12 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Studies assessing mirikizumab induction doses ranging from 50 to 1000\u2009mg in IBD were systematically searched in PubMed, Embase, Scopus, Web of Science, and Cochrane Library from inception to October 2025. Outcomes included clinical remission, clinical response, endoscopic remission, and histologic remission. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using a fixed-effect model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Across included studies, clinical remission improved significantly with 200 (OR: 5.83, 95% CI: 1.58\u201321.48), 300 (OR: 2.09, 95% CI: 1.44\u20133.02), and 900\u2009mg (OR: 3.23, 95% CI: 2.20\u20134.75), while 50 and 600\u2009mg showed nonsignificant trends. Clinical response was significantly higher for 50-, 200-, 300-, and 600-mg doses, with the strongest effect observed at 200\u2009mg (OR: 5.89, 95% CI: 2.57\u201312.59). Endoscopic remission was inconsistent at low doses but significantly improved at 300 (OR: 2.13, 95% CI: 1.56\u20132.91), 900 (OR: 6.16, 95% CI: 3.69\u201310.29), and 1000\u2009mg (OR: 16.06, 95% CI: 2.03\u2013126.91). Histologic remission improved significantly with 200, 300, and 600\u2009mg, while the 50-mg dose showed no meaningful benefit. Overall, mid- to high-dose mirikizumab consistently demonstrated superior efficacy compared with placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Mirikizumab provides dose-dependent therapeutic benefits during induction therapy in IBD. Doses of 200 to 1000\u2009mg, particularly 300 and 900\u2009mg, offer the most consistent improvements across clinical, endoscopic, and histologic outcomes. These findings support the use of mid- to high-dose mirikizumab as an effective induction option in patients with IBD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000047508","type":"journal-article","created":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T17:02:26Z","timestamp":1769965346000},"page":"e47508","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of mirikizumab induction therapy in inflammatory bowel disease: A systematic review and meta-analysis"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5315-9934","authenticated-orcid":false,"given":"Sajjad Ahmed","family":"Khan","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Birat Medical College Teaching Hospital, Morang, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Marasini","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, West Virginia University Health System Princeton Community Hospital, Princeton, West Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bushra","family":"Khanam","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Universal Hospital, Kapilvastu, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisha","family":"Shrestha","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, MedStar Health Georgetown University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadab","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Liceo de Cagayan University, Cagayan de Oro City, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huma","family":"Kausar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Karnali Academy of Health Sciences, Jumla, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heena","family":"Kauser","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Pokhara University, Pokhara, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surya Bahadur","family":"Parajuli","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Birat Medical College Teaching Hospital, Morang, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ejaz","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Jaber Al Ahmad Al Sabah Hospital, Kuwait."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260519","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/jgh3.12706","article-title":"Immune-mediated inflammatory diseases of the gastrointestinal tract: beyond Crohn\u2019s disease and ulcerative colitis.","volume":"6","author":"Vuyyuru","year":"2022","journal-title":"JGH Open"},{"key":"R2-20260519","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/apt.15097","article-title":"Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease.","volume":"49","author":"Shivaji","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"R3-20260519","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.gastro.2024.05.036","article-title":"Targeting the interleukin 23 pathway in inflammatory bowel disease.","volume":"168","author":"Bourgonje","year":"2025","journal-title":"Gastroenterology"},{"key":"R4-20260519","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2174\/187152812800392805","article-title":"The IL23\/Th17 pathway as a therapeutic target in chronic inflammatory diseases.","volume":"11","author":"Toussirot","year":"2012","journal-title":"Inflamm Allergy Drug Targets"},{"key":"R5-20260519","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1124\/jpet.122.001512","article-title":"Generation and characterization of mirikizumab, a humanized monoclonal antibody targeting the p19 subunit of IL-23.","volume":"387","author":"Steere","year":"2023","journal-title":"J Pharmacol Exp Ther"},{"key":"R6-20260519","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis.","volume":"388","author":"D'Haens","year":"2023","journal-title":"N Engl J Med"},{"key":"R7-20260519","first-page":"915","article-title":"Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease.","volume":"10","author":"Pineton de Chambrun","year":"2016","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R8-20260519","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1053\/j.gastro.2019.08.043","article-title":"Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis.","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"R9-20260519","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/S0140-6736(24)01762-8","article-title":"Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn\u2019s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.","volume":"404","author":"Ferrante","year":"2024","journal-title":"Lancet"},{"key":"R10-20260519","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1053\/j.gastro.2021.10.050","article-title":"Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with Crohn\u2019s disease.","volume":"162","author":"Sands","year":"2022","journal-title":"Gastroenterology"},{"key":"R11-20260519","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s40262-023-01281-z","article-title":"Mirikizumab pharmacokinetics in patients with moderately to severely active ulcerative colitis: results from phase III LUCENT studies.","volume":"62","author":"Chua","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"R12-20260519","doi-asserted-by":"crossref","first-page":"otac044","DOI":"10.1093\/crocol\/otac044","article-title":"Clinical effect of mirikizumab treatment on bowel urgency in patients with moderately to severely active ulcerative colitis and the clinical relevance of bowel urgency improvement for disease remission.","volume":"5","author":"Dubinsky","year":"2023","journal-title":"Crohns Colitis 360"},{"key":"R13-20260519","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.3748\/wjg.v23.i35.6385","article-title":"Time to clinical response and remission for therapeutics in inflammatory bowel diseases: what should the clinician expect, what should patients be told?","volume":"23","author":"Vasudevan","year":"2017","journal-title":"World J Gastroenterol"},{"key":"R14-20260519","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/ibd\/izad119","article-title":"Histological disease activity as predictor of clinical relapse, hospitalization, and surgery in inflammatory bowel disease: systematic review and meta-analysis.","volume":"30","author":"Shehab","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"R15-20260519","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1080\/14728222.2024.2433124","article-title":"Targeting mucosal healing in Crohn\u2019s disease: efficacy of novel pathways and therapeutic targets.","volume":"28","author":"Centanni","year":"2024","journal-title":"Expert Opin Ther Targets"},{"key":"R16-20260519","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1097\/MIB.0000000000000046","article-title":"A systematic review of the measurement of endoscopic healing in ulcerative colitis clinical trials: recommendations and implications for future research.","volume":"20","author":"Samaan","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"R17-20260519","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.crohns.2014.08.011","article-title":"Systematic review: histological remission in inflammatory bowel disease. Is \u201ccomplete\u201d remission the new treatment paradigm? An IOIBD initiative.","volume":"8","author":"Bryant","year":"2014","journal-title":"J Crohns Colitis"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047508","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:03:20Z","timestamp":1779195800000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047508","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"2025-11-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}